SECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/in Clinical Trial, Metastatic, Phase 2/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTransdermal Estradiol Patches Show Promise as a Safer Alternative to Traditional Hormone Therapy in Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxASCO GU 2025: New Drug CBP-1018 Shows Promise for Advanced Prostate Cancer in Clinical Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025
- CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC December 11, 2025